NewLimit Raises $130M to Advance Gene Reprogramming for Human Longevity, Reaches $810M Valuation

San Francisco, CA, May 6, 2025 (NewLimit) -- NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised $130 million in Series B funding led by Kleiner Perkins, bringing its valuation to $810 million. The company focuses on gene reprogramming to extend human lifespan, a field Armstrong sees as underinvested. This funding signals increasing investor interest in longevity science and supports NewLimit’s next phase of development.

Read full article here.